Forkhead transcription factor FoxO3a has been reported to have ambiguous functions and distinct mechanisms in various solid tumors, including glioblastoma (GBM). Although a preliminary analysis of a small sample of patients indicated that FoxO3a aberrations in glioma might be related to aggressive clinical behavior, the clinical significance of FoxO3a in glioblastoma remains unclear. We investigated the expression of FoxO3a in a cohort of 91 glioblastoma specimens and analyzed the correlations of protein expression with patient prognosis. Furthermore, the functional impact of FoxO3a on GBM progression and the underlying mechanisms of FoxO3a regulation were explored in a series of in vitro and in vivo assays. FoxO3a expression was elevated in glioblastoma tissues, and high nuclear FoxO3a expression in human GBM tissues was associated with poor prognosis. Moreover, knockdown of FoxO3a significantly reduced the colony formation and invasion ability of GBM cells, whereas overexpression of FoxO3a promoted the colony formation and invasion ability. The results of in vivo GBM models further confirmed that FoxO3a knockdown inhibited GBM progression. More, the pro-oncogenic effects of FoxO3a in GBM were mediated by the activation of c-Myc, microtubule-associated protein 1 light chain 3 beta (LC3B) and Beclin1 in a mixedlineage leukemia 2 (MLL2)-dependent manner. These findings suggest that high FoxO3a expression is associated with glioblastoma progression and that FoxO3a independently indicates poor prognosis in patients. FoxO3a might be a novel prognostic biomarker or a potential therapeutic target in glioblastoma.
with other ERBBs, leading to their autophosphorylation and subsequent activation of the downstream phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT/PKB), which subsequently phosphorylates FoxO3a and leads to its degradation in the cytoplasm. [9] [10] [11] [12] [13] Thus, downregulation of FoxO3a promotes tumor proliferation and metastasis in breast cancer and clear cell renal cell carcinoma. 7, 14 FoxO3a integrates cellular signals that control glioblastoma stem-like cell (GSC) differentiation and carcinogenesis, suggestive of its tumor suppressor function. 15 In recent years, accumulating evidence has revealed new functions of FoxO3a, including stress response, longevity and tumorigenesis. [16] [17] [18] [19] [20] FoxO3a protein levels increase after serum withdrawal and promote tumor cell survival under stress conditions, such as oxidative stress and serum deprivation. [21] [22] [23] Furthermore, FoxO3a interacts with b-catenin and synergistically regulates sets of genes involved in tumor metastasis. 13, 24 FoxO3a also promotes tumor cell invasion through the induction of matrix metalloproteinases. 20, 25 Moreover, FoxO3a mediates self-renewal and tumorigenicity in GSCs, and suppression of FoxO3a in GSCs enhanced response to radiotherapy, indicating that FoxO3a is vital for GSCs survival after radiotherapy. 8, 26 Consistently, FoxO3a is also an important factor in EGFR-targeted chemotherapy resistance in breast cancer. 27, 28 Given that the divergent functions of FoxO3a are found in many tumors, the precise pathophysiological function of FoxO3a in cancer is complicated and remains unclear in GBM.
In addition to regulating the transcription of proapoptotic factors, FoxO3a is critical in regulating cell autophagy. [29] [30] [31] [32] FoxO3a maintains a gene expression program in hematopoietic stem cells that induces autophagy. 32 Autophagy, a cellular self-digestion process that provides energy and nutrients during stress, always accompanies cell death or survival. Autophagy and Akt promote survival in glioblastoma. 33 In addition, researchers showed that inhibiting autophagy intrinsically overcomes current chemo-and radiotherapeutic approaches. [34] [35] [36] Unveiling the critical factors regulating autophagy is a major challenge in the treatment of GBM.
The Cancer Genome Atlas (TCGA) project contains largescale GBM data, including mRNA and protein expression. To our surprise, we found that high levels of FoxO3a protein combined with high levels of ErbB2 or downstream IGF-BP2 protein are associated with an extremely poor prognosis, suggesting that FoxO3a might have alternative functions in GBM. Although a preliminary analysis of a small sample of glioma patients indicated that FoxO3a aberrations in glioma might be related to aggressive clinical behavior, 37 the clinical significance of FoxO3a in GBM is far from clear. Thus, we investigated the expression of FoxO3a in a cohort of 91 glioblastoma specimens and analyzed protein expression correlation with patient characteristics, clinical and pathological variables and patient survival. We further investigated the functional impact and underlying molecular mechanisms of FoxO3a on GBM progression in a series of in vitro and in vivo assays. These data provide novel insights into the role of FoxO3a in GBM progression and identify a potential therapeutic target in patients with GBM.
Material and Methods

Survival analysis from TCGA database
Processed gene expression data (mRNA and protein) and clinical data for GBM were downloaded from TCGA. After standardization, genewise expression values were divided into high-expression and low-expression groups of equal size. For the combination of two genes, samples were grouped as high expression only if the expression of both genes was high and vice versa. Kaplan-Meier survival estimates were then obtained for patients in each group. The Mantel-Haenszel test was used to assess the survival difference between these two groups. The analyses were applied to both overall and progression-free survival.
Patients and tissue samples
Our study was approved by the Ethics Committee of the Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. Written consent was obtained from patients or guardians on behalf of the minors enrolled in the study. Ninety-one patients with histologically confirmed GBM at Ren Ji Hospital, Shanghai Jiao-Tong University between January 2005 and December 2013 were recruited for this study. Their diagnoses were independently rereviewed by two pathologists and classified by WHO criteria. The mean age of patients at diagnosis was 49.38 6 15.87 years (range, 13-85 years), with 46 males and 45 females. Follow-up data were available in 83 patients (range, 0.03-59 months; mean, 14.74 6 13.13 months). Among them, five paired fresh GBM cancerous tissues and adjacent normal tissues were collected.
What's new? Genetic aberrations in forkhead transcription factor (FoxO3a) are thought to play a role in aggressive glioblastoma (GBM), though the nature of their involvement remains unclear. In this study, high FoxO3a expression was positively correlated with GBM progression and poor prognosis in patients. In cells, FoxO3a was found to promote GBM progression via activation of c-Myc and the autophagy-related proteins LC3B and Beclin1. FoxO3a pro-oncogenic effects were mediated by the epigenetic factor MLL2. In addition, in mice, FoxO3a knockdown inhibited GBM progression. The findings suggest that FoxO3a is a potential prognostic biomarker or therapeutic target in GBM.
Tumor Markers and Signatures
Qian et al.
Western blot
To analyze the expression of FoxO3a, Western blot assays were performed using the following primary antibodies: rabbit anti-human FoxO3a (cat 12829, Cell Signalling Technology; 1:1000) and mouse anti-actin (Millipore; 1:10,000). Briefly, tissues were lysed with RIPA buffer (50 mM TrisHCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 0.5% Nadeoxycholate) containing protease inhibitors (Roche, CompleteMini); 20-30 lg samples of the lysates were separated on 8-12% SDS-PAGE gels and transferred to PVDF membranes. The membranes were incubated with primary antibodies overnight at 48C. The primary antibody incubation was followed by incubation with an HRP-conjugated secondary antibody. The bound antibodies were detected using an ECL kit (Pierce, PI32209).
Immunohistochemistry
In total, tissue microarray blocks containing 91 cases of GBM and 63 cases of low-grade gliomas were constructed using Microarrayer. Serial 4-lm sections were obtained from each block, with the first slide stained with H&E to confirm the pathologic diagnosis, and the subsequent slides were stained for further immunohistochemistry.
Tissue microarray slides were routinely deparaffinized and rehydrated. The monoclonal antibody against FoxO3a (1:100 dilutions, cat 12829, Cell Signalling Technology, USA) was used as the primary antibody. For antigen retrieval, the slides were heated at 988C in a citrate buffer (pH 9.0) for a total of 20 min and cooled naturally to room temperature. Sections were incubated in 0.3% hydrogen peroxide for 20 min to inactivate endogenous peroxides. The sections were blocked with 5% normal horse serum in PBS for 30 min and then incubated with the primary antibody overnight at 48C. The sections were then stained using a highly sensitive streptavidin-biotin-peroxidase detection system and counterstained with hematoxylin. A negative control was also incorporated using pre-immune IgG instead of the primary antibody.
Evaluation of immunohistochemistry
Two sections per GBM specimen were independently evaluated by two pathologists. Immunoreactive staining was characterized quantitatively according to the percentage of positive cells and staining intensity without prior knowledge of any of the clinicopathological information. We assigned the following proportion scores: 0 if 0% of the tumor cells showed positive staining, 1 if 0-10% were stained, 2 if 11-50% were stained, 3 if 51-75% were stained and 4 if 75-100% were stained. We rated the intensity of staining on a scale of 0-3: 0, negative; 1, weak; 2, moderate; 3, strong. We then combined the proportion and intensity scores to obtain a total score (range 0-12). All patients were designated as negative (score 0), low (score 1-4), moderate (score [5] [6] [7] [8] or high (score 9-12) groups based on FoxO3a expression.
Cell culture
The human GBM cell lines U87-MG, U251-MG (purchased from the Cell Bank of the Shanghai Branch of the Chinese Academy of Sciences, 2014), U373 and T98G were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and maintained in a humidified atmosphere with 5% carbon dioxidehumidified atmosphere at 378C.
Lentiviral vector-mediated FoxO3a or MLL2-knockdown
FoxO3a shRNAs sequences were 5 0 -GCTCTTGGTGGATCA TCAA-3 0 (FoxO3a-KD1) and 5 0 -GCATGTTCAATGGGAGC TTGGA-3 0 (FoxO3a-KD2). The MLL2 shRNA sequence was 5 0 -TTTCCATTTCTTGAGGCGA-3 0 . After 48 h, the knockdown efficiency was confirmed via quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot.
Lentiviral vectors for human FoxO3a-shRNA carrying a green fluorescent protein (GFP) sequence were constructed by Hanyin Co. (Shanghai, China). The recombinant FoxO3a knockdown lentivirus and the negative control (NC) lentivirus (GFP-lentivirus; Hanyin Co. Shanghai, China) were prepared and titred to 10 9 TU/ml (transfection unit). To obtain the stable FoxO3a-knockdown cell line, U87-MG and T98G cells were seeded in six-well dishes at a density of 2 3 10 5 cells per well.
The cells were then infected with the same titre virus with 8 lg/mL Polybrene on the following day. Approximately 72 h after viral infection, GFP expression was confirmed under a fluorescence microscope, and the culture medium was replaced with selection medium containing 4 lg/ml puromycin. The cells were then cultured for at least 14 days. The puromycinresistant cells were amplified in medium containing 2 lg/ml puromycin for 7-9 days and then transferred to a medium without puromycin. The cells were designated as FoxO3a-KD or NC cells.
Retrovirus-mediated gene expression
FLAG-tagged FoxO3a were cloned into the pMSCV-IRES-GFP vector. For overexpression of FoxO3a, U87-MG and T98G cells were transfected by viral supernatant from 293 T cells transfected with FoxO3a or control vector. The clones were designated as FoxO3a-OE or NC cells.
Colony formation assay
U87-MG cells and T98G with or without FoxO3a knockdown or overexpression were examined. Briefly, 1 ml of 0.8% agar (low melting point agarose) was added to each well (6-well plate) and allowed to set as the base agar. Then, cells were trypsinized, and 500 cells/well (0.5 ml) were seeded. For plating, 0.5 mL pre-warmed DMEM with 20% FBS and 0.5 ml 0.8% agar was added to tubes with cells. The mixture was gently mixed, and 1 mL was added to each replicate in triplicate. The assay was incubated at 378C in a humidified incubator for 10-14 days. Wells were stained with 1 mL of 0.005% crystal violet for 1 h before counting colonies under a dissecting microscope.
Matrigel-transwell assay
Cells were then plated in the top chamber of Transwell assay inserts (Millipore, Billerica, MA) with a Matrigel-coated membrane containing 8-lm pores in 200 lL of serum-free RPMI 1640 medium. The assays were conducted in triplicate. The inserts were then placed into the bottom chamber of a 24-well plate containing RPMI 1640 with 10% FBS as a chemoattractant. After 24 hr, the top layer of the insert was scrubbed with a sterile cotton swab to remove any remaining cells. The invading cells on the bottom surface were stained with 0.1% crystal violet, examined, counted and imaged using digital microscopy. The number of cells in five random fields of each chamber was counted, and an average number of cells were calculated.
Xenograft animal model
US National Institutes of Health and institutional guidelines for animal welfare and experimental conduct were followed. CMV-Cre lentivirus was purchased from Hanyin Biotech (Shanghai, China). Briefly, 2 lL of virus suspension of the 7.6 lg/mL CMV-Cre lentivirus were injected into right striatum over 5 min after FoxO3a KD or control lentivirus injection the week before (Coordinates: 1 mm anterior, 2 mm lateral to the bregma and 3 mm deep from the cortical surface). 39 Mice were monitored for the development of tumors by magnetic resonance imaging (MRI) or bioluminescence by i.p. injection of 150 mg/kg luciferin in PBS using a Xenogen IVIS 200 imaging system (Xenogen Corporation).
Statistical analysis
Survival was calculated starting from the date of surgery to date of death or last follow-up. Survival curves for FoxO3a were plotted using the Kaplan-Meier method and compared using the log-rank test. Median time and hazard ratio were shown with 95% confidence interval (CI). All statistical analyses were performed using SPSS for Windows v.17.0 (SPSS, Chicago, IL). All results were considered significant at twosided p values <0.05.
Results
High nuclear FoxO3a expression in human GBM tissues associated with poor prognosis
The expression of FoxO3a in freshly collected GBM tissues (n 5 5) and normal brain tissues (n 5 5) were analyzed by Western blot. As shown in Figure 1 , FoxO3a was upregulated in GBM compared to normal tissues (Fig. 1a) . Furthermore, we analyzed expression of FoxO3a in 91 patients with GBM using immunostaining analysis. Representative expression patterns in glioblastoma samples are presented in Figure 1b . FoxO3a staining revealed mainly nuclear localization in GBM tissues (Fig. 1b) which can be blocked with an excess of the recombinant human FoxO3a protein, indicating the specificity of the anti-FOxO3a antibody (Supporting Information, Fig. S1 ). All cases were distributed into four groups based on the expression of FoxO3a in GBM samples: negative group (n 5 0), low nuclear FoxO3a expression group (n 5 26), moderate nuclear FoxO3a expression group (n 5 25) or high nuclear FoxO3a expression group (n 5 40) (Fig. 1c) .
To evaluate the association of FoxO3a expression with patient prognosis, GBM cases were further divided into the high and low nuclear FoxO3a expression groups. Log-rank tests and Kaplan-Meier analyses were introduced to assess the effect of FoxO3a expression on patient survival. Patients with low nuclear levels of FoxO3a expression in tumor tissues exhibited significantly longer OS compared with patients with high nuclear FoxO3a expression (n 5 83, P 5 0.000, Fig.  1d ). As shown in Table 1 , the median survival time of patients with low FoxO3a expression was 13 months (n 5 32, 95% CI: 7.87-18.13), whereas the median survival time of patients with high FoxO3a expression was only 8 months (n 5 51, 95% CI: 4.28-11.72). The log-rank test (univariate analysis) revealed that patients with high expression had a significantly reduced overall survival time (v 2 5 13.3, P 5 0.00; Table 1 ).
To further confirm the prognostic relevance of FoxO3a expression in GBM, correlation analysis of protein expression of FoxO3a, ErbB2, IGFBP2 alone or in combination of FoxO3a with either ErbB2 or IGFBP2 with patient overall survival was performed using the TCGA database. Although higher expression of FoxO3a, ErbB2 or IGFBP2 alone in tumors was not significantly related to overall survival in patients with GBM, the combination of high levels of both FoxO3a and ErbB2 or FoxO3a and IGFBP2 was significantly associated with poor prognosis (Fig. 1e) . It might be noteworthy that the mRNA level of FoxO3a, ErbB2, IGFBP2 alone or in any combinations was not correlated with the overall survival ( Supporting Information, Fig. S2 ).
Knockdown of FoxO3a reduced GBM cell colony formation and invasion ability
To illustrate the functions of FoxO3a in GBM progression, we examined the expression of FoxO3a in GBM cells, the western blot result showed that the expression of FoxO3a
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Qian et al. was universal and at similar level in the GBM cells (Fig. 2a) . We then effectively knocked down FoxO3a in U87-MG and T98G cells (Figs. 2b and 2c) . Then, the functions of FoxO3a in the invasion and anchorage-independent growth ability of GBM cells were assessed. The Matrigel-Transwell invasion assay indicated that the suppression of FoxO3a reduced the invasive ability of GBM cells (Figs. 2d-2g) . The soft agar colony formation assay demonstrated that knockdown of FoxO3a significantly suppressed the number of colonies (Figs. 2h, 2i, 2k, and 2l) . Moreover, the size of each colony was also significantly reduced after FoxO3a knockdown (Figs. 2j and 2m). Together, these findings suggest that FoxO3a is crucial in promoting the progression and invasive phenotype of GBM cells.
Overexpression of FoxO3a enhanced GBM cell colony formation and invasion
To further understand the role of FoxO3a in GBM progression, we constructed FoxO3a expression of lentivirus and overexpressed FoxO3a in U87-MG and T98g cells (Figs. 3a  and 3b ). The effects of FoxO3a on GBM cell colony formation and invasion were assessed. The Matrigel invasion assay indicated that overexpression of FoxO3a enhanced the invasive ability of GBM cells (Figs. 3c-3f) . The soft agar colony formation assay demonstrated that overexpression of FoxO3a significantly elevated the number of colonies (Figs. 3g, 3h, 3j , and 3k). Moreover, the size of each colony was also significantly increased after FoxO3a overexpression (Figs. 3i and  3l) . Collectively, these findings provide evidence that elevated FoxO3a expression promotes GBM cell tumorigenesis and invasion.
Suppression of FoxO3a inhibits GBM progression in vivo
To determine the in vivo effect of FoxO3a on GBM progression, we injected FoxO3a KD-1, FoxO3a KD-2 and negative control (NC) cells subcutaneously into female nude mice to emulate the progression of GBM. After 6 weeks, we observed significant differences in the knockdown groups. The mice injected with NC cells developed larger tumors compared with mice inoculated with FoxO3a knockdown cells (Fig. 4a) . The total tumor weight was also decreased approximately twofold in the mice injected with FoxO3a KD cells (p < 0.01 vs control; Fig. 4b ).
In addition to the xenograft animal model, we further investigated the function of FoxO3a in female transgenic high-grade glioma mice. 27 High-grade glioma was successfully induced after CMV-Cre lentivirus injection in three groups (n 5 6). Tumors were monitored by MRI, bioluminescence imaging and H&E staining. Knockdown of FoxO3a was verified by Western blotting analysis of the formed tumor tissues (Fig. 4d) . Suppression of FoxO3a significantly reduced tumor growth and invasion (Figs. 4c-4f) . A subline of U87-NC, U87-FoxO3a KD or U87-FoxO3a OE was implanted into the corpus striatum of athymic nude mice. After 16 days, at which point a few animals started to show signs of morbidity, mice in each experimental group were assessed by MRI to confirm intracranial tumor formation (Fig. 4g) . We found that in vivo tumor growth in the FoxO3a KD group was much slower than control group. In contrast, overexpression of FoxO3a resulted in significantly increased tumor volume compared with the control group. Consistent with the tumor growth data, mice implanted with FoxO3a-OE cells died within 28 days, whereas 100% of the control mice survived for that duration with a median survival of 31.5 days. Strikingly, knockdown of FoxO3a dramatically prolonged survival of the mice compared with the control group (median survival 44.5 days vs 31.5 days, p < 0.01) (Fig. 4h) . Taken together, these results suggest that FoxO3a is critical for GBM progression in vivo.
FoxO3a regulates the transcription of c-myc, LC3B and Beclin1 in GBM cells
Given that FoxO3a is a transcriptional factor, we then searched the FOXO consensus elements in gene promoter regions and found that c-myc, which is an important survival gene in essential cancer and autophagy genes, as well as LC3B and Beclin2 contain putative elements that resemble the consensus elements (Fig. 5a ). To assess the functionality of these elements, we generated three mutants (c-MYCp MUT, LC3bp MUT and BECN1p MUT) in which the respective elements were disrupted (Fig. 5a) . The luciferase reporter assay demonstrated that FoxO3a-induced increases in promoter activity were inhibited by mutation of the downstream putative FOXO binding elements in cells (Fig. 5b) . c-Myc, LC3B and Beclin2 protein levels were analyzed in U87-MG cells and T98G cells with altered FoxO3a expression. Knockdown of FoxO3a in U87-MG cells significantly reduced cMyc, LC3B and Beclin2 protein levels, whereas overexpression of FoxO3a in T98G cells significantly elevated c-Myc, LC3B and Beclin2 protein levels (Figs. 5c and 5d) . Moreover, Western blot results showed that the silencing of FoxO3a resulted in a decrease in the mRNA levels of c-Myc, LC3B and Beclin2 (Fig. 5e) . On the contrary, overexpression of FoxO3a increased c-Myc, LC3B and Beclin2 mRNA levels (Fig. 5f ). Moreover, in tumor tissues collected from transgenic glioma models, reduced c-Myc, LC3B and Beclin2 protein levels were also found in FoxO3a knockdown groups (Fig.  5g) , suggesting that FoxO3a partially promotes GBM progression via the regulation of c-Myc, LC3B and Beclin1 transcription in GBM cells. Given that FoxO3a is associated with chemoresistance, we assessed whether FoxO3a is involved in 
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Qian et al. GBM chemoresistance. We established temozolomide (TMZ)-resistant U87-MG cells by gradually increasing TMZ concentration. The IC50 of TMZ-resistant U87-MG cells was approximately fivefold increase compared to original wildtype U87-MG. Western blotting results revealed that FoxO3a, c-Myc, LC3B and Beclin2 expression was upregulated in TMZ-resistant U87-MG cells compared with wild-type cells (Fig. 5h) . These data indicated that FoxO3a is important for GBM progression and therapy and may partially regulate the transcription of c-Myc, LC3B and Beclin1 in GBM cells.
MLL2 mediates the pro-oncogenic function of FoxO3a in GBM
How does FoxO3a regulate c-Myc, LC3B and Beclin1? The epigenetic factor MLL2 functions downstream of FoxO3a in breast cancer. 27 We examined the FoxO3a/MLL2 axis in GBM. MLL2 was efficiently knocked down in T98G-FoxO3a OE cells (Fig. 6a) . The Matrigel-Transwell assay showed that inhibition of MLL2 reduced the invasion ability in T98g-FoxO3a OE cells (Figs. 6b and 6c) . Consistently, the soft agar colony formation assay found that the number of colonies 
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Qian et al. and the colony size were reduced after MLL2 knockdown inT98G-FoxO3a OE cells (Figs. 6d-6f) . Western blot results further showed that MLL2 knockdown suppressed the expression of c-Myc, LC3B and Beclin1 (Figs. 6g and 6h) . These results revealed that MLL2 mediates the pro-oncogenic function of FoxO3a in GBM.
Discussion
The extremely aggressive and highly infiltrative nature of GBM restrains the effectiveness of current GBM treatments, and novel prognostic markers and targets of therapeutic response are urgently needed. However, the underlying mechanisms of GBM progression remain largely unknown. In this study, we found that FoxO3a was highly expressed in a cohort of GBM tissues, and FoxO3a was associated with poor prognosis, indicating that FoxO3a might be a novel biomarker and therapeutic target for GBM. Moreover, our study reveals a new function of FoxO3a in promoting GBM progression and invasion through activation of c-Myc and the essential autophagy components LC3B and Beclin1 in an MLL2-dependent manner (Fig. 6i) . This novel mechanism partially explained the function of FoxO3a in chemotherapy/radiotherapy resistance. Upregulated FoxO3a in TMZ-resistant GBM cells might confer resistance. Given that that FoxO3a and ERBB2/IGF-BP2 are collectively associated with patient prognosis, targeting ERBB2 with an antibody, such as lapatinib, and synergistically with autophagy inhibitors might be an alternative treatment for GBM.
The function and underlying molecular mechanisms of FoxO3a in cancer progression are multifaceted and remain elusive. In several types of tumors, FoxO3a is downregulated and serves as a tumor suppressor. [40] [41] [42] [43] Shi et al. 37 reported that FoxO3a expression was negatively correlated with the malignant grade of glioma, and low expression of FoxO3a was associated with poor patient outcome. we have analyzed the expression of Foxo3a in low-grade glioma (n 5 63) by IHC and found that 71.4% of low-grade gliomas were Foxo3 positive (Supporting Information, Table 1 ), which is consistent with a previous report by Shi et al. 37 However, in Shi et al.'s report, only 12 patients with grade IV were enrolled in the study such that the sample size was too small to reach sufficient statistical power for the comparison (p 5 0.061) although low expression of FoxO3a tended to be associated with poor patient outcome. In this study, we found that patients with grade IV gliomas that expressed high levels of FoxO3a had poor survival (p < 0.001; n 5 83). The plausible explanation for this discrepancy might be related to novel functions of FoxO3a in resistance to radiotherapy and chemotherapy that account for poor clinical outcome. Recently, it has been reported that FoxO3a functions to maintain the stemness and survival of GBM stem cells thus conferring resistance of gliomas to radiotherapy. 8, 44 Moreover, an observation that FOXO3a positively regulates c-Myc to reduce sensitivity of breast cancer cells to Lapatinib or AKT inhibitor provides a new insight into a role that FOXO3a plays in chemoresistance. 27 However, consistent with our study, FoxO3a exhibits a stronger immunostaining in the nucleus of breast cancer cells compared with benign breast tissues and predicts poor survival. 45 In acute myeloid leukemia, the viability of leukemia stem cells depends on the expression of FoxO3a. 46 These complex observations emphasize the heterogeneous nature of malignant diseases and underscore the complicated dual function of FoxO3a. The expression and function of FoxO3a are tightly controlled by PI3K/AKT-associated phosphorylation and ubiquitination pathways. However, in cancerous tissues, upstream PI3K/AKT regulation might be reduced, and FoxO3a might function as a tumor enhancer. Therefore, the precise function and mechanisms of FoxO3a must be further studied to fully address the clinical potential of FoxO3a in GBM. Several studies showed that FoxO3a protected cells from apoptosis and promoted invasion and metastasis under stress conditions through regulation of nuclear factor jB (NF-jB) signaling and transcriptional regulation of genes involved in cell migration. 9, 20, [47] [48] [49] In this study, we investigated the function of FoxO3a in vitro and in vivo models. These data showed that FoxO3a is important for GBM cell growth and invasion through upregulating the crucial survival gene c-Myc and the essential autophagy components LC3B and Beclin1 in an MLL2-dependent manner. In addition to c-Myc, LC3B and Beclin1, there are more transcriptional targets that may participate in the function of FoxO3a in GBM, such as MMPs. Although MLL2 is associated with FoxO3a in breast cancer cells, 27 how FoxO3a associates with MLL2 in GBM cells requires further study.
In conclusion, our study found that FoxO3a might function as an independent prognostic factor in GBM. Our findings may add an additional layer to the complexity of the roles of FoxO3a in cancer and provide a novel prognostic biomarker or therapeutic target in the management of glioblastoma.
